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	 Simple,	 sensitive	 and	 precise	 spectrophotometric	 and	 chemometric	 stability	 indicating	
techniques	were	adopted	for	Olanzapine	(OLA)	determination	in	presence	of	its	degradation	
products	 over	 a	 concentration	 range	 of	 0.002‐0.02	 mg/mL.	 The	 spectrophotometric	
technique	involves	six	methods;	first	method	is	first	derivative	(D1)	spectrophotometric	one,	
which	 allows	 the	 determination	 of	 OLA	 in	 presence	 of	 its	 acidic	 and	 alkaline	 degradation	
products	 at	 261.2	 and	 260.6	 nm	 with	 mean	 percentage	 recoveries	 of	 99.90±0.48	 and	
99.95±0.67,	 respectively.	 While	 second	 derivative	 spectrophotometry	 (D2)	 was	 used	 for	
determination	of	drug	in	presence	of	alkaline	degradation	products.	Second	method	is	first‐
derivative	of	the	ratio	spectra	(DR1)	for	determination	of	OLA	in	presence	of	its	acidic	and	
alkaline	 degradation	 products	 at	 267.9	 and	 251.6	 nm,	 respectively	with	mean	 percentage	
recoveries	 of	 99.81±0.64	 and	 100.53±1.11,	 respectively.	 The	 third	 method	 is	 pH‐induced	
difference	 method	 for	 determination	 of	 OLA	 in	 presence	 of	 its	 acidic	 and	 alkaline	
degradation	 products;	 with	 mean	 percentage	 recoveries	 100.09±0.06	 and	 99.77±0.78,	
respectively.	Fourth	method	is	the	Q‐analysis	(absorption	ratio)	method,	which	involves	the	
formation	of	absorbance	equation	at	296.3	nm	(isosbestic	point)	and	271	nm	(λmax	of	OLA)	
for	 the	 determination	 of	 OLA	 in	 presence	 of	 its	 acidic	 degradation	 products.	 The	 mean	
percentage	recovery	 is	100.07±1.51.	Fifth	method	based	on	dual	wavelength	selection	was	
developed	for	the	determination	of	OLA	in	presence	of	its	acidic	degradation	products	with	
mean	 percentage	 recovery	 of	 100.36±0.69.	 Sixth	 method	 based	 on	 simple	 mathematic	
algorithm	by	the	bivariate	calibration	was	also	used	for	the	determination	of	OLA	with	the	
mean	 percentage	 recovery	 of	 101.72±1.10.	 The	 second	 technique	 is	 chemometrics,	 which	
includes	 determination	 of	 OLA	 in	 presence	 of	 its	 acidic	 degradation	 products	 using	
multivariate	 calibration	 methods	 (the	 classical	 least	 squares	 (CLS),	 principle	 component	
regression	 (PCR)	 and	 partial	 least	 squares	 (PLS))	 using	 the	 information	 contained	 in	 the	
absorption	spectra.	
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Bivariate	calibration	
Derivative	spectrophotometer	
	
1.	Introduction	
	
Olanzapine;	 2‐methyl‐4‐(4‐methyl‐1‐piperazinyl)‐10H‐
thieno[2,3‐b][1,5]benzodiazepine	 (Figure	 1)	 is	 a	 second‐gene‐
ration	 antipsychotic	 drug,	 used	 in	 treatment	 of	 schizophrenia	
and	 prescribed	 mainly	 for	 patients	 with	 prominent	 agitation	
and	 insomnia	 [1].	 OLA	 also	 may	 help	 with	 weight	 gain	 in	
anorexia	 nervosa	 [1].	 The	 exact	 mechanism	 by	 which	 OLA	
exerts	its	antipsychotic	effect	is	unknown.	However,	this	effect	
may	 be	 mediated	 through	 a	 combination	 of	 dopamine	 and	
serotonin	antagonism	[1].	Olanzapine	is	metabolized	primarily	
through	 oxidation	 mediated	 by	 cytochrome	 P450	 (CYP)	
enzymes	 and	 by	 direct	 glucuronidation.	 The	 two	 major	
metabolites,	10‐N‐glucuronide	and	4´‐N‐desmethyl	olanzapine,	
are	not	pharmacologically	active	at	the	plasma	levels	achieved	
[1].	OLA	could	be	determined	by	several	analytical	techniques,	
titrimetric	 methods	 [2‐4],	 spectroscopic	 methods	 including	
colorimetric	 [5‐15],	 U.V.	 spectrophotometric	 [16‐18],	 and	
fluorimetric	 [18]	 methods.	 OLA	 can	 also	 be	 determined	 by	
electrochemical	 methods	 [17,18],	 capillary	 electrophoresis	
[19],	and	thin	layer	chromatography	[20‐24].	High	performance	
liquid	chromatographic	 [HPLC]	methods	were	widely	used	for	
analysis	of	OLA	in	pure	form	[25‐57].	OLA	was	also	successfully	
determined	using	gas	chromatography	[58].	Chemometrics	was	
applied	for	simultaneous	determination	of	OLA	and	Fluoxetine	
[59].		
	
	
	
Figure	1.	Chemical	structure	of	intact	olanzapine.	
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2.	Experimental	
	
2.1.	Instrumentation	
	
A	 double	 beam	 UV‐VIS	 spectrophotometer	 (UV‐1800,	
Japan)	 connected	 to	 IBM	 compatible	 computer.	 The	 bundled	
software	is	UV	probe	software	version	2.32	(Shimadzu)	and	the	
spectral	 bandwidth	was	0.1	 nm.	 The	 absorption	 spectra	were	
carried	 out	 using	 1	 cm	 quartz	 cells.	 The	 chemometric	
calculations	were	performed	in	Matlab	for	Windows‐version	7	
Mathworks	 Inc.2004.	 The	 PLS	 procedure	was	 taken	 from	PLS	
Toolbox	 2.1,	 Eigenvector	 Research	 Inc.	 2001	 created	 by	 B.M.	
Wise,	N.B.	Gallagher	for	use	with	Matlab.	
	
2.2.	Materials	and	reagents	
	
All	chemicals	were	of	analytical	grade,	the	solvents	were	of	
spectroscopic	grade.		
OLA	 was	 kindly	 supplied	 by	 Egyptian	 International	
Pharmaceutical	 Industries	Company	 (Eipico)	 10th	 of	 Ramadan	
City,	Egypt.	 Its	purity	was	100.45±0.30%	(n	=	5)	 according	 to	
the	reported	method	[16].	
Olanza®5mg	 tablets,	 labeled	 to	 contain	 5	 mg	 of	 OLA	 per	
tablet	manufactured	by	Egyptian	International	Pharmaceutical	
Industries	 Company	 (Eipico)	 10th	 of	 Ramadan	 City,	 Batch	
No.1821O07	and	purchased	from	the	local	market.	
Sodium	hydroxide,	hydrochloric	acid	(Adwic‐Cairo,	Egypt),	
methanol	(Analar‐Germany).		
	
2.3.	Standard	solutions	of	the	intact	OLA	
	
Stock	 solution:	 A	 standard	 stock	 solution	 of	 OLA	 was	
prepared	by	accurately	transferring	100	mg	of	pure	drug	into	a	
100	 mL	 volumetric	 flask,	 dissolving	 in	 20	 mL	 methanol	 and	
then	 the	 volume	 was	 completed	 to	 the	 mark	 with	 the	 same	
solvent	 to	 provide	 standard	 stock	 solution	 containing	 1.00	
mg/mL.		
Working	solution:	OLA	working	solution	(0.02	mg/mL)	was	
prepared	 by	 transferring	 2	mL	 of	 the	 standard	 stock	 solution	
into	 100	 mL	 volumetric	 flask	 and	 then	 the	 volume	 was	
completed	to	the	mark	with	methanol.		
	
2.4.	Preparation	of	standard	solution	of	acidic	and	alkaline	
degraded	OLA	
	
50	mg	of	OLA	was	mixed	with	25	mL	of	2	M	hydrochloric	
acid	 one	 time	 and	 4	 M	 sodium	 hydroxide	 another	 time	 and	
refluxed	 for	 6	 hours.	 The	 solutions	 were	 cooled,	 neutralized	
with	 2	 M	 aqueous	 sodium	 hydroxide	 and	 4	 M	 aqueous	
hydrochloric	acid	respectively,	till	pH	=	7,	transferred	to	50	mL	
volumetric	flasks	and	diluted	to	the	mark	with	methanol	(1.00	
mg/mL).	Aliquot	portions	of	these	solutions	were	diluted	with	
methanol	 to	 prepare	 working	 standard	 solutions	 of	 0.02	
mg/mL.	
Complete	degradation	was	confirmed	was	confirmed	by	the	
reported	 HPLC	method,	 using	 inertsil	 C18	 column	 (5	 μm,	 150	
mm	×	4.6	mm	i.d).	The	mobile	phase	was	a	mixture	of	9.5	mM	
sodium	 dihydrogen	 phosphate	 (pH	 adjusted	 to	 6.8±0.1	 with	
triethylamine),	 acetonitrile	 and	 methanol	 (40:30:30,	 by	
volumes)	and	UV	detection	at	225	nm	[46].	
The	 previously	 prepared	 solutions	 were	 evaporated	 to	
dryness.	 Then	 the	 degradation	 products	 were	 extracted	 with	
multiple	fraction	of	methanol	(3	×	10	mL).	Then	the	extract	was	
evaporated	at	room	temperature	and	the	degradation	products	
were	 collected.	 The	 degradation	 products	 powder	 was	
elucidated	by	IR	and	mass	spectrometry.		
	
2.5.	Procedures	
	
2.5.1.	Construction	of	calibration	curves	for	D1	and	D2	
spectrophotometric	method	
Accurately	 measured	 volumes	 of	 intact	 OLA	 working	
solution	(0.02	mg/mL)	were	transferred	into	a	series	of	10	mL	
volumetric	 flasks	 and	 diluted	 to	 the	 mark	 with	 methanol	 to	
obtain	concentrations	from	0.002	to	0.02	mg/mL.	The	D1	and	D2	
spectra	of	each	solution	was	recorded	using	Δλ	=	8	and	scaling	
factor	=	100.	For	determination	of	OLA	in	presence	of	its	acidic	
degradation	 products	 a	 calibration	 curve	 was	 obtained	 by	
plotting	 the	 peak	 amplitudes	 of	 D1	 at	 261.2	 nm	 versus	 the	
corresponding	 drug	 concentrations.	 While	 for	 OLA	
determination	in	presence	of	its	alkaline	degradation	products	
the	peak	amplitudes	of	D1	and	D2	at	260.6	and	239.9	nm	were	
recorded,	 respectively	 (corresponding	 to	 zero‐crossing	 of	 the	
degradation	product)	versus	the	corresponding	concentrations	
of	drug,	and	regression	equations	were	computed.	
	
2.5.2.	Construction	of	calibration	curves	of	(DD1)	
spectrophotometric	method	
	
Different	 aliquots	 of	 intact	 OLA	 working	 solution	 (0.02	
mg/mL)	 were	 accurately	 transferred	 into	 a	 series	 of	 10	 mL	
volumetric	 flasks	 and	 diluted	 to	 the	 mark	 with	 methanol	 to	
obtain	 concentrations	 from	 0.002	 to	 0.02	 mg/mL.	 The	 DD1	
curves	 were	 recorded	 at	 Δλ	 =	 8	 and	 scaling	 factor	 =	 10.	 The	
absorption	 spectra	 of	 these	 solutions	 were	 divided	 by	 the	
absorption	spectrum	of	0.004	mg/mL	of	the	acidic	and	alkaline	
degradation	 products	 separately	 (as	 divisors).	 The	 obtained	
ratio	 spectra	 were	 then	 differentiated	 with	 respect	 to	
wavelength.	The	peak	amplitudes	at	267.9	and	251.6	nm	were	
recorded	for	the	determination	of	OLA	in	presence	of	its	acidic	
and	alkaline	degradation	products,	respectively.	The	calibration	
curves	 representing	 the	 relationship	 between	 the	 measured	
amplitudes	 and	 the	 corresponding	 concentrations	 of	 the	 drug	
were	constructed	and	the	regression	equations	were	computed.		
	
2.5.3.	Construction	of	calibration	curves	for	pH‐induced	
difference	method	
	
Accurately	 measured	 volumes	 of	 intact	 OLA	 working	
solution	(0.02	mg/mL)	were	transferred	into	two	sets	of	10	mL	
volumetric	 flasks,	diluting	the	first	set	 to	 the	mark	with	0.1	M	
NaOH	 and	 the	 second	 set	 with	 0.1	 M	 HCl	 to	 obtain	
concentration	range	from	0.002	to	0.02	mg/mL.	The	Zero‐order	
spectrum	 of	 each	 dilution	 was	 recorded	 against	 its	
corresponding	 blank.	 The	 previous	 spectra	 of	 each	 dilution	
were	 computed,	 to	 give	 (ΔA)	 spectra.	 The	peak	 amplitudes	 of	
(ΔA)	 spectra	 were	 recorded	 at	 240	 and	 247.9	 nm	 for	
determination	 of	 ((OLA)	 in	presence	 of	 its	 acidic	 and	 alkaline	
degradation	 products	 respectively	 (Corresponding	 to	 zero‐
crossing	 of	 the	degradation	products)	 and	plotted	 against	 the	
corresponding	concentrations	of	OLA.	The	regression	equations	
were	then	computed.		
	
2.5.4.	Construction	of	calibration	curves	for	Q‐analysis	
(absorption	ratio)	method	
	
Accurately	measured	 volumes	 of	 intact	OLA	 and	 its	 acidic	
degradation	 products	 working	 solutions	 were	 transferred	
separately	into	a	series	of	10	mL	volumetric	flasks	and	diluted	
to	the	mark	with	methanol	to	obtain	concentrations	from	0.002	
to	0.02	mg/mL.	The	Zero‐order	spectrum	of	each	dilution	was	
recorded	against	methanol	as	a	blank.	The	absorbance	of	OLA	
and	its	acidic	degradates	were	measured	at	296.3	and	271	nm	
for	 each	 dilution	 separately.	 Then	 the	 absorbance	 at	 the	
selected	 wavelengths	 was	 plotted	 against	 the	 corresponding	
concentrations	 and	 the	 regression	 equations	 were	 then	
computed.	 Absorptivity	 coefficients	 of	 OLA	 and	 its	 acidic	
degradation	 products	 were	 determined	 at	 both	 selected	
wavelengths;	 the	 absorption	 equation	 was	 then	 formed.	 The	
concentration	 of	 the	 drug	 of	 interest	 is	 calculated	 from	 the	
equation.	
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2.5.5.	Construction	of	calibration	curve	for	dual	wave	length	
method	
	
Accurately	 measured	 volumes	 of	 intact	 OLA	 working	
solution	(0.02	mg/mL)	were	transferred	into	a	series	of	10	mL	
volumetric	 flasks	 and	 diluted	 to	 the	 mark	 with	 methanol	 to	
obtain	 concentrations	 from	 0.002	 to	 0.02	 mg/mL.	 The	 Zero‐
order	spectrum	of	each	dilution	was	recorded	against	methanol	
as	 blank.	 The	 absorbance	 of	 OLA	 was	 measured	 at	 270	 and	
246.3	 nm	 for	 each	 dilution	 separately.	 Then	 the	 difference	
between	 the	 absorbance	 at	 the	 selected	 wavelengths	 was	
calculated,	plotted	against	the	corresponding	concentrations	of	
the	drug	and	the	regression	equation	was	then	computed.		
	
2.5.6.	Construction	of	calibration	curve	for	bivariate	
spectrophotometric	method	
	
Accurately	 measured	 volumes	 of	 OLA	 and	 its	 acidic	
degradation	 products	 working	 solutions	 were	 transferred	
separately	into	a	series	of	10	mL	volumetric	flasks	and	diluted	
to	the	mark	with	methanol	to	obtain	concentrations	from	0.002	
to	0.02	mg/mL	for	both	OLA	and	its	acidic	degrades.	The	Zero‐
order	spectrum	of	each	dilution	was	recorded	against	methanol	
as	 blank.	 The	 absorbance	 of	 OLA	 and	 its	 acidic	 degradation	
products	were	measured	at	229	and	245	nm	for	each	dilution	
separately.	 Then	 the	 absorbance	 values	 at	 the	 selected	
wavelengths	 were	 plotted	 against	 the	 corresponding	
concentrations	 and	 the	 regression	 equations	 were	 then	
computed.	
	
2.5.7.	Multivariate	calibration	technique	(Chemometric)	
	
(a)	 Construction	 of	 training	 set‐Different	mixtures	 of	OLA	
and	its	acidic	degradation	products	were	prepared	by	diluting	
different	 volumes	of	 their	working	 standard	 solutions	 into	10	
mL	 volumetric	 flask	 and	 completing	 to	 the	 final	 volume	with	
methanol.	 The	 absorbance	 of	 these	 mixtures	 was	 measured	
between	240‐370	nm	at	1	nm	interval	with	respect	to	a	blank	of	
methanol.	 The	 composition	 of	 the	 samples	 was	 randomly	
designed	according	to	five	level	calibration	design	[60]	in	order	
to	 obtain	 non	 correlated	 concentration	 profiles	 and	 this	
calibration	design	prepared	to	obey	Beer’s	law.	
(b)	 Constructing	 the	models‐To	build	 the	 CLS	model,	 feed	
the	computer	with	absorbance	and	concentration	matrices	 for	
training	set.	Carry	out	the	calculations	to	obtain	the	“K”	matrix.	
For	 the	 PCR	 and	PLS	models,	 use	 the	 training	 set	 absorbance	
and	 concentration	 matrices	 together	 with	 PLS‐Toolbox	 2.0	
software	for	the	calculations.	
(c)	Construction	of	the	validation	set.	Prepare	different	nine	
mixtures	 of	 OLA	 and	 its	 acidic	 degradation	 products	 by	
transferring	 different	 volumes	 of	 their	 working	 standard	
solutions	into	a	series	of	10	mL	volumetric	flasks	and	complete	
to	 volume	 with	 methanol.	 Apply	 the	 developed	 models	 to	
predict	the	concentration	of	OLA	in	each	mixture.	
	
2.5.8.	Laboratory	prepared	mixtures	
	
Solutions	containing	different	ratios	of	OLA	and	up	to	60%	
of	its	acidic	and	60%	of	its	alkaline	degradation	products	were	
prepared	to	obtain	mixture	solutions	of	intact	drug	and	both	its	
degradation	products	separately.	
	
2.5.9.	Application	to	pharmaceutical	preparation	
	
Ten	tablets	were	accurately	weighed	and	finely	powdered.	
A	portion	equivalent	 to	50	mg	of	OLA	was	weighed,	sonicated	
in	 20	mL	methanol	 and	 filtered	 into	 50	mL	 volumetric	 flask.	
The	residue	was	washed	three	times	each	with	8	mL	methanol	
and	 completed	 to	 the	 mark	 with	 the	 same	 solvent.	 Aliquots	
(according	 to	 linearity)	 was	 transferred	 to	 10	mL	 volumetric	
flasks	and	diluted	with	methanol.	The	general	procedures	were	
followed	and	the	concentration	of	OLA	was	calculated	from	its	
corresponding	regression	equation.	
	
3.	Results	and	discussion	
	
The	 International	 Conference	 on	 Harmonization	 (ICH)	
guideline	 entitled	 “stability	 testing	 of	 new	 drugs	 substances	
and	products”	requires	the	stress	testing	of	new	substances	and	
products,	 also	 requires	 the	 stress	 testing	 to	 be	 carried	 out	 to	
elucidate	 the	 inherent	 stability,	 characteristics	 of	 the	 active	
substance	[61].	An	ideal	stability	indicating	method	is	one	that	
quantifies	 the	 standard	 drug	 alone	 and	 also	 resolves	 its	
degradation	products.	
The	 structures	 of	 the	 intact	 drug,	 acidic	 and	 alkaline	
degradation	 products	 were	 elucidated	 by	 IR	 and	 mass	
spectrometry.	The	major	acidic	degradation	product	suggested	
in	 acidic	 conditions	 is	 2‐[(2‐aminophenyl)amino]‐N‐ethenyl‐
N,5‐dimethylthiophene‐3‐carboxamide	as	presented	in	(Figure	
2).	 While	 in	 case	 of	 alkaline	 conditions,	 2‐[(2‐aminophenyl)	
amino]‐5‐methylthiophene‐3‐carboxylic	 acid	 (I)	 and	 4‐methyl	
piperazin‐1‐amine	 (II)	 are	 suggested	 to	 be	 the	 major	
degradation	product	(Figure	3).	
	
 
	
Figure	2.	Scheme	for	acidic	degradation	of	OLA.	
	
	
	
 
	
Figure	3.	Scheme	for	alkaline	degradation	of	OLA.	
	
The	 IR	 spectrum	 of	 OLA	 showed	 a	 characteristic	 band	 at	
3217.7	cm‐1	indicating	the	presence	of	NH	group,	and	a	band	at	
2932.9	cm‐1	indicating	the	presence	of	Alkane	C‐H	bonds.	While	
IR	 spectrum	 of	 the	 acidic	 degradates	 showed	 a	 characteristic	
broad	band	at	3541.5	cm‐1,	indicating	the	presence	of	OH	group	
and	another	two	characteristic	bands	at	3483.8	and	3398.2	cm‐
1	indicating	the	presence	NH2	group	while	the	appearance	of	a	
band	at	1639.2	cm‐1	suggest	the	presence	of	C=O	group.	The	IR	
spectrum	of	the	alkaline	degradation	products	showed	charac‐
teristic	 broad	 band	 at	 3439.1	 cm‐1,	 indicating	 the	 presence	 of	
OH	group	and	a	band	at	2360.6	cm‐1	suggesting	the	presence	of	
C≡N	group,	and	a	band	at	1634.0	cm‐1	suggest	the	presence	of	
C=O	group.	
While	 the	 mass	 spectrum	 showed	 characteristic	 peaks	 at	
m/z	287.11	and	45	in	case	of	acidic	degradation	and	at	248.06	
and	115.11	in	case	of	alkaline	degradation.	
The	major	 acidic	 degradation	 product	 suggested	 is	 2‐[(2‐
aminophenyl)amino]‐N‐ethenyl‐N,5‐methylthiophene‐3‐carbox	
amide	 (I)	 and	 dimethylamine	 (II).	 While	 in	 case	 of	 alkaline	
degradation,	 2‐[(2‐aminophenyl)amino]‐5‐methylthio‐phene‐
3‐carboxylic	 acid	 (I)	 and	 4‐methylpiperazin‐1‐amine	 (II)	 are	
suggested	to	be	the	major	degradation	product	.	
The	 focus	 of	 the	 present	 work	 was	 to	 develop	 accurate,	
specific,	reproducible	and	sensitive	stability	indicating	methods	
for	 the	 determination	 of	 OLA	 in	 pure	 form	 and	 in	
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pharmaceutical	 formulation	 in	 the	 presence	 of	 acidic	 and	
alkaline	degradation	products.		
The	 zero‐order	 absorption	spectrum	of	OLA	and	 its	 acidic	
and	 alkaline	 degradation	 products	 showed	 sever	 overlapping	
(Figure	4	and	5)	which	interfere	with	the	direct	determination	
of	OLA.	
	
	
Figure	4.	 Zero	 order	 spectra	 of	 OLA	 (___)	 and	 acidic	 degradation	 products	
(…)	(10	ug/mL	each)	using	methanol	as	a	solvent.	
	
	
	
Figure	 5.	 Zero	 order	 spectra	 of	 OLA	 (___)	 and	 of	 alkaline	 degradation	
products	(‐‐‐)	(10	ug/mL	each)	using	methanol	as	a	solvent.	
	
3.1.	Derivative	spectrophotometry	
	
A	 rapid,	 simple	and	 low	cost	 spectrophotometric	methods	
based	 on	 measuring	 the	 peak	 amplitude	 of	 D1	 at	 261.2	 nm	
(Figure	6)	and	260.6	nm	(Figure	7)	for	determination	of	OLA	in	
presence	 of	 its	 acidic	 and	 alkaline	 degradation	 products	
respectively	 and	 also	 measuring	 the	 peak	 amplitude	 of	 D2	 at	
239.9	nm	(Figure	8)	for	determination	of	OLA	in	presence	of	its	
alkaline	degradation	products	(corresponding	to	zero	crossing	
of	 the	 degradation	 products)	 were	 developed	 with	 good	
selectivity	 without	 interference	 of	 its	 acidic	 and	 alkaline	
degradation	 products	 over	 concentration	 range	 from	 2‐20	
ug/mL.	
In	 order	 to	 optimize	 D1	 and	 D2	 methods,	 different	
smoothing	and	scaling	factors	were	tested,	where	a	smoothing	
factor	Δλ =	8	and	scaling	factor	=	100	showed	a	suitable	signal	
to	noise	ratio	and	the	spectra	showed	good	resolutions.	
The	 proposed	methods	 are	 valid	 for	 the	 determination	 of	
OLA	in	presence	of	its	acidic	and	alkaline	degradation	products	
in	different	laboratory	prepared	mixtures.		
	
3.2.	DR1	method	
	
In	order	to	improve	the	selectivity	of	the	analysis	of	OLA	in	
presence	 of	 its	 acidic	 and	 alkaline	 degradation	 products	 DR1	
method	was	established.	
	
Figure	6. First	derivative	absorption	spectra	of	10	ug/mL	of	OLA	(__)	and	10	
ug/mL	of	acidic	degradation	products	(….)	using	methanol	as	a	solvent.	
	
	
	
Figure	7.	First	derivative	absorption	spectra	of	10	ug/mL	of	OLA	(___)	and	10	
ug/mL	of	alkaline	degradation	products	(…)	using	methanol	as	a	solvent.	
	
	
	
Figure	8. Second	derivative	absorption	spectra	of	10	ug/mL	of	OLA	(___)	and	
10	 ug/mL	 of	 its	 alkaline	 degradation	 products	 (…)	 using	 methanol	 as	 a	
solvent.	
	
The	 main	 advantage	 of	 the	 method	 is	 that	 the	 whole	
spectrum	 of	 interfering	 substance	 is	 cancelled	 [62].	
Accordingly,	 the	 choice	 of	 the	 wavelength	 selected	 for	
calibration	is	not	critical	as	in	D1	or	D2	derivative	method.		
In	order	to	optimize	DR1	method	for	determination	of	OLA	
in	presence	of	 its	degradation	products,	 it	 is	necessary	 to	 test	
the	influence	of	the	variables:	divisor	concentration,	smoothing	
and	scaling	factors.		
Several	 divisor	 concentrations	 of	 the	 acidic	 and	 alkaline	
degradates	 were	 tried,	 the	 best	 results	 was	 obtained	 when	
using	 0.004	mg/mL	 of	 both	 degradation	 products	 as	 divisors.	
Different	smoothing	and	scaling	factors	were	also	tested	where	
a	 smoothing	 factor	 Δλ	 =	 8	 nm,	 and	 scaling	 factor	 =	 10	 were	
suitable	 to	 enlarge	 the	 signals	 of	 OLA	 to	 facilitate	 its	
measurement	and	to	diminish	error	in	reading	the	signal.		
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DR1	 values	 showed	 good	 linearity	 and	 reproducibility	 at	
267.9	 and	 251.6	 nm	without	 interference	 from	 its	 acidic	 and	
alkaline	degradation	products	respectively	(Figure	9	and	10).	
Linearity	of	the	peak	amplitudes	of	the	DR1	curves	at	both	
wavelengths	was	obtained	in	range	(0.002‐0.02	mg/mL).	
The	 method	 was	 checked	 by	 analysis	 of	 laboratory	
prepared	 mixtures	 of	 OLA	 and	 its	 acidic	 and	 alkaline	
degradation	products	in	different	ratios.	
	
	
Figure	9.	First	derivative	ratio	spectra	of	different	concentrations	of	OLA	(2‐
20	 ug/mL)	 using	 4	 ug/mL	 acidic	 degradation	 products	 as	 a	 divisor	 in	
methanol.	
	
	
	
Figure	10.	 First	derivative	 ratio	 spectra	of	different	 concentrations	of	OLA	
(2‐20	ug/mL)	using	 4	 ug/mL	 alkaline	degradation	 products	 as	 a	 divisor	 in	
methanol.	
	
3.3.	pH‐Induced	difference	(ΔA)	technique	
	
The	 most	 basic	 nitrogen	 atoms	 of	 OLA	 located	 in	 the	
piperazine	ring	are	easily	protonated	resulting	in	considerable	
increase	 in	 the	 angle	 between	 planes	 of	 OLA	 aromatic	 rings	
(benzene	 and	 thiophene).	 Rotation	 of	 the	piperazine	 ring	 and	
change	in	its	conformation	from	twist	to	boat	leads	to	change	in	
the	 spectral	 characteristics	 of	 OLA	 upon	 protonation	 [63].	
Owing	to	this	property,	OLA	was	determined	in	presence	of	its	
acidic	and	alkaline	degradation	products,	in	raw	materials	and	
in	 pharmaceutical	 formulation,	 using	 pH‐induced	 difference	
technique.	
The	absorption	spectra	of	OLA	 in	0.1	M	sodium	hydroxide	
and	 in	 0.1	 M	 hydrochloric	 acid	 are	 presented	 in	 (Figure	 11).	
OLA	could	be	quantitatively	determined	at	240	nm	and	247.9	
nm	in	presence	of	its	acidic	and	alkaline	degradation	products,	
respectively	(zero	crossing	point)	without	interference	from	its	
degradation	products,	(Figure	12	and	13).	
	
3.4.	Q‐analysis	(absorption	ratio)	method	
	
Absorbance	 ratio	method	uses	 the	 ratio	of	 absorbances	 at	
two	 selected	 wavelengths	 [64],	 one	 of	 which	 is	 an	 isosbestic	
point	 and	 other	 being	 the	 λ‐max	 of	 OLA.	 From	 the	 overlain	
spectrum	of	 the	 drug	 and	 its	 degradation	 products,	 296.3	nm	
(isoabsorptive	point)	and	271	nm	(λmax	 of	OLA)	were	selected	
for	 the	 determination	 of	 OLA	 in	 presence	 of	 its	 acidic	
degradation	products.	
Linear	calibration	curves	were	obtained	in	the	range	(2‐20	
ug/mL)	for	both	intact	OLA	and	its	acidic	degradation	products	
relating	the	absorbances	at	the	two	selected	wavelengths	296.3	
and	271	nm	to	the	corresponding	concentrations	of	OLA	and	its	
acidic	degradation	products	and	the	regression	equations	were	
computed.	
Absorptivity	 coefficients	 of	 both	 OLA	 and	 its	 acidic	
degradation	products	were	determined	as	shown	in	Table	1.	
	
	
Figure	11. Zero‐order	 absorption	 spectra	 of	OLA	 (10	ug/mL),	 (a)	 in	 0.1	M	
HCl	(…),	(b)	in	0.1	M	NaOH	(‐	‐	‐),	(c)	ΔA	spectra	(__).	
	
	
Figure	12.	ΔA	spectra	of	OLA	(___)	and	its	acidic	degradation	products	(…),	in	
0.1	M	(Hydrochloric	acid	and	sodium	hydroxide)	(each,	10	ug/mL).	
	
	
	
Figure	13.	ΔA	spectra	of	OLA	(__)	and	its	alkaline	degradation	products	(…),	
in	0.1	M	(hydrochloric	acid	and	sodium	hydroxide)	(each,	10	ug/mL).
	
The	concentration	of	OLA	was	determined	by	substituting	
the	 absorbance	 and	 absorptivity	 coefficients	 in	 the	 following	
equation	[65].	
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Table	1.	Absorptivity	coefficient	values	of	Olanzapine	and	acidic	degradation	products	at	296.3	(isosbestic	point)	and	271.0	nm	(λmax	of	OLA).	
Sample	no	 Absorptivity	at	296.3	nm	 Absorptivity	at	271.0	nm	
Olanzapine	 Acidic	deg. Olanzapine Acidic	deg.	
1	 22.0	 22.0 60.5 41.0	
2	 22.5	 21.5 60.7 40.5	
3	 21.8	 21.8 60.1 41.0	
4	 22.1	 21.8	 60.2	 41.0	
5	 22.2	 22.2	 60.7	 41.3	
6	 21.7	 21.9 60.0 41.0	
Mean	 22.05	 21.86	 60.36	 40.96	
	
	
Table	2.	Application	of	the	method	of	Kaiser	for	the	selection	of	the	wavelength	set	for	the	determination	of	olanzapine.	
λ1/λ2	 215	nm	 229	nm	 245	nm 262	nm 271	nm	 300	nm
215	nm	 0	 5.72	 2.81	 1.00	 2.57	 4.91	
229	nm	 0	 7.37	 3.79	 2.49	 6.57	
245	nm	 0	 3.15	 4.54	 3.09	
262	nm	 0 1.27	 4.39		
271	nm	 0 5.09	
300	nm	 0		
	
	
		 	 	 	 (1)	
	
Where	A1	 and	A2	 are	 the	 absorbances	 of	mixture	at	296.3	
and	 271	 nm	 respectively.	 	 and	 are	 the	 absorptivity	
coefficients	 of	 OLA	 at	 296.3	 and	 271	 nm,	 respectively.	 While	
	and	 are	 the	 absorptivity	 coefficients	 of	 acidic	
degradation	 products	 at	 296.3	 and	 271	 nm,	 respectively.	 Qm	
=A2/A1,	Qy=	 / 	and	Qx= / .		
	
3.5.	Dual	wavelength	method	
	
The	 overlain	 spectrum	 of	 OLA	 and	 its	 acidic	 degradation	
products	suggested	 that	dual	wavelength	method	 is	a	 suitable	
method	for	the	simultaneous	determination	of	OLA	in	presence	
of	its	degradation	products	[66].	
From	the	overlain	spectra,	270	and	246.3	nm	were	selected	
for	 the	 determination	 of	 OLA,	 where	 the	 acidic	 degradation	
products	shows	the	same	absorbances.		
A	 linear	 Calibration	 curve	 was	 obtained	 in	 the	 range	
(0.002‐0.02	 mg/mL)	 relating	 the	 difference	 between	 the	
absorbances	at	 the	 two	selected	wavelengths	270.0	and	246.3	
nm	 to	 the	 corresponding	 drug	 concentrations	 in	 presence	 of	
acidic	degradation	products.	
	
3.6.	Bivariate	calibration	method	
	
OLA	 was	 also	 determined	 and	 resolved	 from	 its	 acidic	
degradation	 products	 by	 using	 bivariate	 calibration	
spectrophotometric	method	[67].	
This	method	is	based	on	a	simple	mathematical	algorithm,	
in	which	 the	 data	 is	 used	 derives	 from	 four	 linear	 regression	
calibration	 equations,	 two	 calibrations	 for	 each	 component	 at	
two	wavelengths	selected	using	the	method	of	Kaiser	[68].	The	
method	 has	 been	 successfully	 applied	 to	 resolve	 different	
binary	 mixtures	 [69].	 The	 advantage	 of	 bivariate	 calibration	
method	is	simplicity	and	the	fact	that	derivatization	procedure	
is	not	necessary.	Unlike	other	chemometric	techniques,	there	is	
no	need	for	full	spectrum	information	and	no	data	processing	is	
required.	
The	 linear	 calibration	 regression	 function	 for	 the	
spectrophotometric	 determination	 of	 an	 analyte	 (A)	 at	 a	
selected	wavelength	(i)	is	given	by	AAi=	mAi	CA	+	eAi	where	mAi	is	
the	slope	of	linear	regression,	CA	is	the	concentration	of	analyte	
A	 and	 eAi	 is	 the	 intercept	 value.	 If	 the	 measurement	 of	 the	
binary	 mixture	 (AB)	 are	 performed	 at	 two	 selected	
wavelengths	(λ1,	λ2)	we	have	two	equations	set	[67]	
	
AAB1=mA1CA+mB1CB+eAB1	 	 	 	 (2)	
	
AAB2=mA2CA+mB2CB+eAB2	 	 	 	 (3)	
The	resolution	of	such	equations	set	allows	the	evaluation	
of	 CB	 (concentration	 of	 OLA)	 and	 CA	 (concentration	 of	 acidic	
degradation	products)	from	the	following	equations:	
	
	 	 	 (4)	
	
	 	 	 (5)	
	
These	 simple	 mathematical	 algorithms	 allows	 the	
resolution	of	the	two	components	by	measuring	the	absorbance	
of	OLA	and	degradation	products,	each	at	two	wavelengths	and	
using	 the	 parameters	 of	 the	 linear	 regression	 functions	
evaluated	 individually	 for	 each	 component	 at	 the	 same	
wavelengths.	 The	 method	 of	 Kaiser	 [68]	 was	 used	 for	 the	
selection	 of	 optimum	wavelength	 set	 which	 assured	 the	 best	
sensitivity	 for	 the	 quantitative	 determination	 of	 the	 studied	
drug.	
In	 order	 to	 apply	 this	 method,	 the	 signals	 of	 the	 two	
components	 located	 at	 six	 wavelengths:	 215,	 229,	 245,	 262,	
271,	and	300	nm	were	selected.	
The	calibration	curve	equations	and	their	respective	linear	
regression	 coefficient	 were	 obtained	 directly	 with	 the	 aim	 of	
ensuring	 the	 linearity	 between	 the	 signal	 and	 the	
concentrations.	The	slope	values	of	the	 linear	regression	were	
estimated	for	both	the	drug	and	its	acidic	degradation	products	
at	the	selected	wavelengths	and	used	for	the	determination	of	
the	sensitivity	matrices	K,	which	proposed	by	Kaiser’s	method	
[68].	A	series	of	sensitivity	matrices,	K,	were	created	for	every	
pair	of	pre‐selected	wavelengths.	
	
		 	 	 	 	 (6)	
	
A	=	Acidic	degradate,	B	=	Olanzapine	
	
where	mA1,2	and	mB1,2	are	the	sensitivity	parameters	(slope)	of	
the	 regression	 equation	 of	 A	 and	 B	 at	 the	 two	 selected	
wavelengths	 (λ1	 and	 λ2)	 .	 The	 determinants	 of	 these	matrices	
were	calculated	as	shown	 in	Table	2.	The	wavelength	set	was	
selected	 for	which	 the	 highest	matrix	 determinant	 value	 was	
obtained.	
For	bivariate	determination	of	OLA	in	presence	of	its	acidic	
degradation	products,	229	and	245	nm	wavelengths	were	used.	
Table	3	showed	the	linear	regression	calibration	formula	used	
for	bivariate	algorithm.	
The	 laboratory	 prepared	 mixtures	 were	 analyzed	 by	 the	
proposed	method	 for	determination	of	 intact	OLA	 in	presence	
of	its	acidic	degradation	products	using	the	following	equation		
	
	 	 	 (7)	
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Table	3.	Linear	regression	calibration	formulas	used	for	the	bivariate	algorithm.	
Component	 Calibration	equations	*	
λ	1=229	nm	 λ	1=245	nm
Olanzapine	 A=0.0703C+0.0064	r	=	0.9998	 A=0.0503C‐0.0032	r	=	0.9999	
Acidic	deg.	 A=0.0439C‐0.0035	r	=	0.9997	 A=0.0419C‐0.0035	r	=	0.9997	
*	A	=	Absorbance	at	the	selected	wavelength,	C	=	Concentration	in	ug/mL;	r	=	Correlation	coefficient.	
	
	
Table	4.	The	concentration	of	mixtures	of	OLA,	and	its	acidic	degradate	in	the	training	set.	
Sample	no	 Olanzapine	(ug/mL) Acidic	degradation	products	(ug/mL)	
1	 6	 6	
2	 6	 2
3	 2	 10
4	 10	 4
5	 10	 6
6	 6	 4
7	 4	 8
8	 8	 10	
9	 8	 6
10	 6	 10	
11	 10	 2	
12	 2	 8	
13	 2	 6
14	 6	 8
15	 8	 4
16	 2	 4
	
	
Table	5.	The	concentration	of	mixtures	of	OLA	and	its	acidic	degradation	products	in	the	validation	set.	
Sample	no	 Olanzapine	(ug/mL)	 Acidic	deg.	(ug/mL)	
1	 2	 2
2	 4	 10
3	 4	 4
4	 10	 8	
5	 10	 10	
6	 8	 2	
7	 8	 8
8	 4	 2	
9	 4	 6
	
	
where	 eAB1,	 eAB2	 are	 the	 sum	 of	 intercepts	 of	 the	 linear	
calibrations	at	 the	 two	wavelengths	 (eAB1	 =	 eA1	+	 eB1),	1,	2	 are	
the	wavelengths	229	and	245	nm,	mA,	mB	are	the	slopes	of	the	
linear	regressions	and	C	is	the	concentration	of	OLA.	
	
3.7.	Multivariate	method	
	
In	 this	 section,	 different	 chemometric	 approaches	 were	
applied	 for	 the	determination	of	OLA	 in	presence	of	 its	 acidic	
degradation	 products,	 including	 CLS,	 PCR,	 PLS.	 These	
multivariate	 calibrations	 were	 useful	 in	 spectral	 analysis	
because	 the	 simultaneous	 inclusion	 of	 many	 spectral	
wavelengths	instead	of	single	wavelength	greatly	improved	the	
precision	and	predictive	ability	[60].	
The	 first	 step	 in	 the	 simultaneous	 determination	 of	 two	
components	 by	 multivariate	 calibration	 methods	 involves	
constructing	 the	 calibration	 matrix	 for	 binary	 mixture.	 The	
calibration	set	was	obtained	by	using	the	absorption	spectra	of	
a	set	of	16	mixtures	of	OLA	and	its	acidic	degradation	products	
with	 different	 ratios	 of	 each	 component	 and	 their	
concentrations	are	given	in	Table	4.	
The	model	 selected	was	 that	with	 the	 smallest	number	of	
factors	 such	 that	RMSECV	 for	 the	model	was	not	 significantly	
greater	than	RMSECV	from	the	model	with	additional	factor.	As	
the	 difference	 between	 the	 minimum	 RMSECV	 and	 other	
RMSECV	 values	 became	 smaller,	 the	 probability	 that	 each	
additional	 factor	was	 significant	 became	 smaller.	 Two	 factors	
were	found	to	be	suitable	for	both	PLS	and	PCR	methods.	
The	 UV	 spectra	 of	 the	 prepared	 solutions	 were	 recorded	
over	 the	 range	 240‐370	 nm.	 Wavelengths	 (200‐239	 nm)	
dominated	by	noise	 and	non‐informative	 spectral	 region	after	
370	nm	are	not	included.	Spectra	were	digitized	each	at	0.1nm	
interval,	 and	 the	 experimental	 data	 points	 were	 exposed	 to	
MATLAB	version	7.0	for	calculations.	
To	build	the	CLS	model,	feed	the	computer	with	absorbance	
and	 concentration	 matrices	 for	 training	 set.	 Carry	 out	 the	
calculations	 to	 obtain	 the	 “K”	 matrix.	 For	 the	 PCR	 and	 PLS	
models,	 use	 the	 training	 set	 absorbance	 and	 concentration	
matrices	 together	 with	 PLS‐Toolbox	 2.0	 software	 for	 the	
calculations.	
The	selection	of	the	optimum	number	of	factors	for	the	PLS	
technique	was	 a	 very	 important	 step	 before	 constructing	 the	
models	 because	 if	 the	 number	 of	 factors	 retained	 was	 more	
than	the	required,	more	noise	will	be	added	to	the	data.	On	the	
other	 hand,	 if	 the	 number	 retained	was	 too	 small	meaningful	
data	 that	 could	 be	 necessary	 for	 the	 calibration	 might	 be	
discarded.	 In	 this	 study	 the	 leave	 one	 out	 cross	 validation	
method	was	used	[70,71].	
The	 root	 mean	 square	 error	 of	 prediction	 (RMSEP)	 was	
calculated	 as	 diagnostic	 tool	 for	 examining	 the	 errors	 in	 the	
predicted	 concentrations.	 It	 indicated	 both	 the	 precision	 and	
accuracy	of	predictions	as	 it	played	 the	same	role	of	 standard	
deviation	in	indicating	the	spread	of	the	concentration	errors.	
As	the	difference	between	the	minimum	RMSECV	and	other	
RMSECV	 values	 became	 smaller,	 the	 probability	 that	 each	
additional	factor	was	significant	became	smaller.	After	the	PCR	
and	PLS	models	 have	been	 constructed,	 it	was	 found	 that	 the	
optimum	 number	 of	 latent	 variables	 described	 by	 the	
developed	models	was	two	factors	for	PCR	and	PLS	models.	
Calibration	 graphs	 were	 constructed	 by	 plotting	 the	
predicted	 concentrations	 for	 OLA	 by	 each	 of	 the	 developed	
models	 versus	 the	 true	 concentrations.	 The	 statistical	
parameters	 of	 the	 linear	 relationship	 between	 the	 calculated	
and	 the	 true	 concentration	of	OLA	 in	 the	 calibration	 set	were	
presented.	 In	 order	 to	 assess	 the	 predictive	 ability	 of	 each	 of	
the	developed	models,	it	was	applied	on	an	external	validation	
set	for	determination	of	OLA.		
Table	 5	 shows	 different	 concentrations	 of	 OLA	 and	 its	
acidic	degradation	products	used	in	the	validation	set.		
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Table	6.	Validation	parameters	for	the	proposed	stability‐indicating	spectrophotometric	methods.	
Validation	parameters	
Dn	 DR1	 ΔA	
D1	
261.2	nm	
D1	
260.6	nm
D2	
239.9	nm 267.9	nm 251.6	nm 240	nm	 247.9	nm
Linearity	(µg/mL)	 2‐20	 2‐20 2‐20 2‐20 2‐20 2‐20	 2‐20
Slope	 0.0559	 0.0538 0.0206 0.0972 0.0600 0.1256	 0.1108
Intercept	 ‐0.0006	 0.0006 0.0001 0.0205 ‐0.0040 0.0024	 0.0022
Correlation	coefficient	(r)	 0.9999	 0.9999 0.9999 1 0.9999 0.9999	 0.9999
LOD	(μg/mL)	 0.08	 0.09 0.11 0.25 0.34 0.229	 0.259
LOQ	(μg/mL)	 0.25	 0.29 0.35 0.75 1.05 0.695	 0.785
Precision	 Intra‐day	a	 1.27	 0.15	 0.13	 0.16	 0.06	 0.92	 0.84	
Inter‐day	b	 1.04	 0.29	 0.21	 0.26	 0.31	 0.61	 0.50	
Validation	parameters	 Q‐Analysis	method Dual	wave	length method Bivariate	calibration	method
296.3	nm	 271	nm	 247.9	nm	 229	nm	 245	nm	
Linearity	(µg/mL)	 2‐20	 2‐20 2‐20 2‐20	 2‐20
Slope	 0.2196	 0.0602	 0.0102	 0.0703	 0.0502	
Intercept	 0.00053	 0.0010	 ‐0.0022	 0.0064	 ‐0.0032	
Correlation	coefficient	(r)	 0.9998	 0.9999	 0.9998	 0.9998	 0.9999	
LOD	(μg/mL)	 0.369	 0.158 0.277 0.4642	 0.2557
LOQ	(μg/mL)	 1.119	 0.481	 0.839	 1.4066	 0.7749	
Precision	 Intra‐day	a	 1.19	 0.12 0.46	
Inter‐day	b	 0.98	 0.67 0.62	
a	The	intraday	(n	=	3)	average	of	three	concentrations	(6,	10,	and	14)	repeated	three	times	within	day.		
b	The	interday	(n	=	9)	average	of	three	concentrations	repeated	three	times	in	three	successive	days.	
	
	
Table	7.	 Results	 of	 assay	 validation	 obtained	by	 applying	 the	proposed	chemometric	methods	 for	 the	determination	 of	Olanzapine	 in	presence	of	 its	 acidic‐
degradation	products.	
Validation	parameters	 CLS	 PCR	 PLS	
Predicted	versus	actual	concentration	plot	
Slope	 0.9995 1.0051	 0.9995
Intercept	 0.0023	 0.0194	 0.0024	
Correlation	coefficient	(r)	 1.0000 0.9999	 1.0000
RMSEP	 0.0035	 0.0318	 0.0036	
	
	
Table	8.	Determination	of	the	studied	drug	in	the	laboratory	prepared	(L.P.)	mixtures	with	its	degradation	products	and	in	tablets	by	the	proposed	methods	.	
Sample	 Dn	‐method	a	 DR1	‐method	a ΔA‐method	a	
D1	
261.2	nm	
D1	
260.6	nm	
D2	
239.9	nm	 267.9	nm	 251.6	nm	 240	nm	 247.9	nm	
L.P.‐mixtures	
(n	=	5)	b	
100.49±0.32	 100.93±0.63	 100.93±0.63 99.86±0.09 100.80±0.38 99.86±0.17	 99.53±0.38
Up	to	60%	degradation	
Olanza	tablets	5	mg,	
B.N.1821O07	
100.50±1.41	 99.90±0.48 99.96±0.32 99.98±0.30 100.65±0.60 100.73±0.65	 99.64±0.89
Sample	 Q‐Analysis	
method	a	
Dual	wave	length	
method	a	
Bivariate	calibration
method	a	
CLS	a PCR	a	 PLS	a
L.P.‐mixtures	
(n	=	5)	b	
99.96±0.13	 101.47±0.67 100.97±0.13 99.98±0.08	 100.10±0.32	 100.01±0.08
Up	to	60%	degradation	 Up	to	50%	degradation	
Olanza	tablets	5	mg,	
B.N.1821O07	
100.64±1.08	 99.72±1.06 100.87±1.38 99.96±0.32	 99.90±0.48	 100.50±1.41
a	Recovery±RSD.	
b	Sets	each	of	3	replicates.	
	
	
Table	9.	Application	of	the	standard	addition	technique	to	the	analysis	of	the	studied	drug	by	the	proposed	methods.	
Pharmaceutical	
preparation	
Authentic	
added	
(ug/mL)	
Standard	addition,	Recovery%	**	
D1	 D2 DR1 ΔA	
261.20	nm	 260.60	nm	 239.90	nm	 267.9	nm	 251.6	nm	 240	nm	 247.9	nm	
Olanza®tablets*	
5mg	
B.N.	1821O07	
2	 99.47	 98.54 98.57 100.41 101.49 99.69	 100.61
4	 102.95	 99.89	 99.35	 100.20	 101.08	 101.25	 99.94	
6	 99.64	 99.83 99.93 99.79 100.11 101.34	 99.12
8	 100.22	 100.58 100.58 99.71 100.24 100.58	 98.37
10	 100.21	 99.83 100.37 99.77 100.33 100.77	 100.17
Mean	 100.50	 99.90 99.96 99.98 100.65 100.73	 99.64
SD	 1.41	 0.48	 0.32	 0.30	 0.60	 0.65	 0.89	
Authentic	
added	
(ug/mL)	
Q‐Analysis	
method	
Dual	wave	
length	method	
Bivariate	calibration	
method	
CLS PCR	 PLS
2	 99.46	 101.50 102.09 99.47 99.54	 98.57
4	 100.78	 98.71	 102.29	 102.95	 99.89	 99.35	
6	 99.64	 99.77 99.01 99.64 99.83	 99.93
8	 102.03	 99.42	 100.91	 100.22	 100.58	 100.58	
10	 101.28	 99.19 100.06 100.21 99.83	 100.37
Mean	 100.64	 99.72 100.87 100.50 99.90	 99.96
SD	 1.08	 1.06 1.38 1.41 0.48	 0.32
*	Equivalent	to	10	ug/mL	of	OLA.	
**	Average	of	at	least	3	separate	determinations.	
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Table	 10.	 Statistical	 comparison	 of	 the	 results	 obtained	 by	 the	 proposed	 methods	 and	 the	 reported	 method	 for	 the	 determination	 of	 Olanzapine	 in	
pharmaceutical	preparation.	
Items	 D1	 D2 DR1 ΔA	
261.20	nm	 260.60	nm 239.90	nm 267.9	nm 251.6	nm	 240	nm	 247.9	nm
Mean	 100.46	 100.47 100.36 99.54 99.27 100.10	 99.99
SD	 0.291	 0.301	 0.	32	 0.315	 0.194	 0.521	 0.510	
RSD%	 0.289	 0.300	 0.32 0.315 0.194 0.521	 0.510
n	 5	 5	 5	 5	 5	 5	 5	
Variance	 0.084	 0.091	 0.102 0.099 0.038 0.271	 0.260
Student’s	t‐test	(2.306)	 0.04	 0.06	 0.49 0.915 1.060 1.29	 1.72
F‐test	(6.388)	 1.07	 1.00	 1.37	 1.090	 2.39	 2.97	 2.85	
Items	 Q‐analysis	
method	
Dual	wave	
length	method	
Bivariate	calibration	
method	
CLS PCR PLS	 Reported	
method	*	
Mean	 100.70	 100.38	 100.71	 99.96	 100.02	 99.97	 100.45	
SD	 0.492	 0.231	 0.350 0.360 0.371 0.362	 0.302
RSD%	 0.489	 0.230	 0.347	 0.360	 0.371	 0.362	 0.300	
n	 5	 5	 5 5 5 5	 5	
Variance	 0.242	 0.056	 0.123 0.129 0.137 0.131	 0.091
Student’s	t‐test	(2.306)	 0.95 0.116	 1.22 2.29 2.03 2.29	
F‐test	(6.388)	 2.70 1.63	 1.35 1.41 1.50 1.43	
The	values	between	parenthesis	are	the	theoretical	values	of	t‐test	and	F‐test	at	p	=	0.05.	
*	Direct	derivative	Spectrophotometric	method	where	the	first	derivative	values	were	measured	at	222	nm	in	methanol	[16].	
	
	
To	validate	 the	prediction	ability	of	 the	suggested	models,	
they	 were	 used	 to	 predict	 the	 concentration	 of	 OLA	 in	
laboratory	 prepared	 mixtures	 containing	 different	 ratios	 of	
them.	
Results	 of	 assay	 validation	 obtained	 by	 applying	 the	
proposed	 spectrophotometric	 and	 chemometric	 methods	 for	
the	determination	of	Olanzapine	in	presence	of	its	degradation	
products	are	presented	in	Tables	6	and	7,	respectively.	
The	 proposed	 methods	 were	 applied	 successfully	 to	
analysis	of	OLA	in	pharmaceutical	formulation,	and	the	results	
obtained	were	listed	in	Table	8.	
Standard	 addition	 technique	 was	 successfully	 applied	 for	
the	analysis	of	the	studied	drug	by	the	proposed	methods	and	
results	are	presented	in	Table	9.	
Table	 10	 represents	 statistical	 comparison	 of	 the	 results	
obtained	 by	 the	 proposed	methods	 and	 the	 reported	method	
for	the	determination	of	OLA	in	pharmaceutical	preparation.	
	
4.	Conclusion	
	
The	proposed	methods	are	 simple,	 very	 sensitive,	precise,	
and	can	be	easily	applied	in	QC	laboratories	for	determination	
of	 OLA	 in	 presence	 of	 its	 acidic	 and	 alkaline	 degradation	
products.	 The	 proposed	 methods	 could	 be	 also	 successfully	
applied	for	routine	analysis	of	OLA	either	in	its	bulk	powder	or	
in	 dosage	 form	 in	 QC	 laboratories,	 without	 any	 preliminary	
separation	step.	
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